TransMedics Boosts 2025 Outlook After Q1 Beat
TransMedics stock surged 21% after reporting Q1 revenue of $143.5M—up 48% YoY—and EPS of 70¢, crushing the 29¢ consensus. The company raised full-year revenue guidance
TransMedics stock surged 21% after reporting Q1 revenue of $143.5M—up 48% YoY—and EPS of 70¢, crushing the 29¢ consensus. The company raised full-year revenue guidance
Globus Medical shares fell over 22% after the company missed Q1 expectations and lowered its EPS outlook. Revenue declined 1.4% to $598.1M, with adjusted EPS
SS Innovations announced plans to submit a de novo request to the FDA for its SSi Mantra 3 robotic surgical system this July. The submission
Insulet’s stock jumped over 20% following strong Q1 results that outperformed Wall Street expectations. The company reported $569 million in revenue—a 29% increase year-over-year—and adjusted
MicroTransponder’s Vivistim system continues to demonstrate clinical value in stroke recovery, with new one-year follow-up data revealing sustained improvements in motor function and quality of
Stay ahead in MedTech with industry updates, breakthroughs, and expert
insights—delivered straight to your inbox.
© 2025 MEDWIRE.AI. All rights reserved. MEDWIRE.AI is a trusted source for MedTech news and insights. Our website content and services are for informational purposes only. MEDWIRE.AI does not provide medical advice, diagnosis, or treatment.
